Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
17.20
-0.98 (-5.42%)
Sep 23, 2026, 11:02 AM EDT - Market open
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $72.79M in the quarter ending June 30, 2026, with 91.76% growth. This brings the company's revenue in the last twelve months to $252.25M, up 222.65% year-over-year. In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth.
Revenue (ttm)
$252.25M
Revenue Growth
+222.65%
P/S Ratio
6.44
Revenue / Employee
$846,480
Employees
298
Market Cap
1.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 440.00M |
| Immunocore Holdings | 430.78M |
| AnaptysBio | 232.39M |
| Taysha Gene Therapies | 5.49M |
| Absci | 1.56M |
| Inhibrx Biosciences | 1.30M |
SNDX News
- 8 days ago - Syndax Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 13 days ago - Syndax Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 18 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Syndax Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 weeks ago - Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - Invezz
- 4 weeks ago - Syndax price target lowered to $33 from $37 at UBS - TheFly
- 6 weeks ago - Syndax price target lowered to $40 from $44 at JPMorgan - TheFly
- 7 weeks ago - Syndax price target lowered to $38 from $40 at H.C. Wainwright - TheFly